TrialThe Lancet. Haematology2023

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Justin M Watts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.